The Role of Erythropoietin in Myelodysplastic Syndrome

Completed

• Conditions: Myelodysplastic Syndrome

• Registration Number: NCT00723112
• Lead Sponsor: University of Utah

Brief Summary

The purpose of the study is to elucidate the causative molecular events responsible for the abnormal erythropoiesis in MDS.

Detailed Description

Myelodysplastic syndromes are a heterogeneous group of disorders characterized by clonal expansion of hematopoietic stem cells and ineffective hematopoiesis. Although all 3 cell lineages in myeloid hematopoiesis can be involved, the erythroid dysplasia and ineffective erythropoiesis of MDS are usually the most severe, and often precede the development of other bone marrow lineage defects.

In normal erythropoiesis, erythroid progenitors differentiate and proliferate in response to stimulation by erythropoietin (Epo). Epo binds to its receptor, EpoR, constitutively expressed at the surface of committed erythroid progenitors and induces homodimerization. This study is designed to evaluate the EpoR cDNA sequence and its level of expression in the clonal erythroid progenitors of MDS patients (in cells stratified for the same degree of erythroid maturation) to determine whether mutations in the EpoR may be responsible for an aberrant Epo signal transduction in MDS. As well as analyze intrinsic erythroid Epo expression to determine whether it differs between normal controls and patients with MDS and perform a microarray analysis of genes associated with Epo signal transduction to determine if MDS patients have abnormal expression of signal transduction proteins.

Study Timeline

• Study Start: 2007-02
• Study First Submitted: 2008-07-24
• Study First Submitted QC: 2008-07-25
• Study First Posted: 2008-07-28
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Status Verified: 2010-11
• Last Update Submitted: 2010-11-22
• Last Update Posted: 2010-11-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Adult subjects greater than 18 years of age
• Diagnosis of MDS based on the French-American-British classification system (including secondary causes of MDS)

Exclusion Criteria

• Subjects not meeting the criteria listed above

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the EpoR cDNA sequence and its level of expression in the clonal erythroid progenitors of MDS patients to determine whether mutations in the EpoR may be responsible for an aberrant Epo signal transduction in MDS.	After Samples are obtained

Secondary Outcome Measures

Name	Time	Method
Analyze intrinsic erythroid Epo expression to determine whether it differs between normal controls and patients with MDS.	After samples are obtained
Perform a microarray analysis of genes associated with Epo signal transduction to determine if MDS patients have abnormal expression of signal transduction proteins.	After samples are obtained
Determine how often and what percent clonality occurs in MDS patients and try to predict who has early MDS by clonality testing.	After samples from female patients have been obtained

Trial Locations

Locations (2)

University of Utah; 🇺🇸 Salt Lake City, Utah, United States

VA Salt Lake City Health Care System; 🇺🇸 Salt lake City, Utah, United States